Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 251.90 points (-1.4%) at 17,165 as of Friday, Jan. 30, 2015, 4:20 PM ET. The NYSE advances/declines ratio sits at 1,001 issues advancing vs. 2,121 declining with 101 unchanged.

The Drugs industry as a whole closed the day down 1.2% versus the S&P 500, which was down 1.3%. Top gainers within the Drugs industry included Reliv' International ( RELV), up 2.5%, Oragenics ( OGEN), up 3.0%, Parnell Pharmaceuticals Holdings ( PARN), up 4.8%, Acura Pharmaceuticals ( ACUR), up 5.0% and NovaBay Pharmaceuticals ( NBY), up 3.2%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

Parnell Pharmaceuticals Holdings ( PARN) is one of the companies that pushed the Drugs industry higher today. Parnell Pharmaceuticals Holdings was up $0.20 (4.8%) to $4.40 on light volume. Throughout the day, 200 shares of Parnell Pharmaceuticals Holdings exchanged hands as compared to its average daily volume of 13,100 shares. The stock ranged in a price between $4.37-$4.40 after having opened the day at $4.37 as compared to the previous trading day's close of $4.20.

Parnell Pharmaceuticals Holdings has a market cap of $55.8 million and is part of the health care sector. Shares are up 1.2% year-to-date as of the close of trading on Thursday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close, Oragenics ( OGEN) was up $0.02 (3.0%) to $0.79 on light volume. Throughout the day, 12,053 shares of Oragenics exchanged hands as compared to its average daily volume of 37,500 shares. The stock ranged in a price between $0.77-$0.83 after having opened the day at $0.78 as compared to the previous trading day's close of $0.77.

Oragenics, Inc. focuses on the discovery, development, and commercialization of various technologies associated with oral health, antibiotics, and other general health benefits. Oragenics has a market cap of $28.9 million and is part of the health care sector. Shares are down 10.1% year-to-date as of the close of trading on Thursday. Currently there are no analysts who rate Oragenics a buy, no analysts rate it a sell, and 1 rates it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Oragenics as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on OGEN go as follows:

  • OGEN's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 78.98%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, ORAGENICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • The revenue fell significantly faster than the industry average of 42.0%. Since the same quarter one year prior, revenues fell by 20.6%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
  • Net operating cash flow has increased to -$1.10 million or 44.14% when compared to the same quarter last year. Despite an increase in cash flow of 44.14%, ORAGENICS INC is still growing at a significantly lower rate than the industry average of 118.68%.
  • The gross profit margin for ORAGENICS INC is rather high; currently it is at 66.67%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of -512.43% is in-line with the industry average.

You can view the full analysis from the report here: Oragenics Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Reliv' International ( RELV) was another company that pushed the Drugs industry higher today. Reliv' International was up $0.03 (2.5%) to $1.21 on light volume. Throughout the day, 5,742 shares of Reliv' International exchanged hands as compared to its average daily volume of 17,700 shares. The stock ranged in a price between $1.16-$1.21 after having opened the day at $1.16 as compared to the previous trading day's close of $1.18.

Reliv' International, Inc. develops, manufactures, and markets nutritional supplements that promote basic nutrition, weight loss, athletic performance, digestive health, women's health, anti-aging, and healthy energy. Reliv' International has a market cap of $14.9 million and is part of the health care sector. Shares are up 0.8% year-to-date as of the close of trading on Thursday. Currently there are no analysts who rate Reliv' International a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Reliv' International as a hold. The company's strengths can be seen in multiple areas, such as its expanding profit margins and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, feeble growth in the company's earnings per share and deteriorating net income.

Highlights from TheStreet Ratings analysis on RELV go as follows:

  • The gross profit margin for RELIV INTERNATIONAL INC is currently very high, coming in at 80.94%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of 1.15% trails the industry average.
  • Although RELV's debt-to-equity ratio of 0.27 is very low, it is currently higher than that of the industry average. Although the company had a strong debt-to-equity ratio, its quick ratio of 0.87 is somewhat weak and could be cause for future problems.
  • RELV, with its decline in revenue, underperformed when compared the industry average of 5.8%. Since the same quarter one year prior, revenues fell by 13.4%. The declining revenue appears to have seeped down to the company's bottom line, decreasing earnings per share.
  • RELIV INTERNATIONAL INC's earnings per share declined by 50.0% in the most recent quarter compared to the same quarter a year ago. The company has reported a trend of declining earnings per share over the past two years. During the past fiscal year, RELIV INTERNATIONAL INC reported lower earnings of $0.06 versus $0.10 in the prior year.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Personal Products industry. The net income has significantly decreased by 43.3% when compared to the same quarter one year ago, falling from $0.29 million to $0.17 million.

You can view the full analysis from the report here: Reliv' International Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.